Introdução: A vigilância intensiva pós-operatória do carcinoma colo-retal permite a deteção da recorrência em fase assintomática, aumentando o número de doentes que podem beneficiar de nova cirurgia. Implementámos um programa de vigilância de doentes com carcinoma colo-retal estádios II-III, operados com intenção curativa, com avaliação clínica, tomografia computorizada e colonoscopia. O presente estudo teve como objectivos avaliar a taxa de cirurgia de intenção curativa, a taxa de mortalidade por cancro e identificar características clínicas associadas à irresecabilidade da recidiva. 
INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers in the world. The worldwide incidence of CRC is 17.2 per 100 000 person-years. CRC is the third most incident cancer in men and the second most incident in women. 1 Patients with CRC American Joint Committee on Cancer (AJCC) stage II or III are treated with curative-intent surgical resection and may also receive chemotherapy and/ or radiotherapy. Despite these treatments approximately 30% to 50% will have disease recurrence. 2, 3 About 90% of these recurrences present in the first 5 years after curative surgery, and most often in first three years after surgery. [2] [3] [4] [5] The purpose of postoperative surveillance programs after curative surgery for colorectal cancer (CRC) is to detect asymptomatic recurrences, and to identify new metachronous neoplasms at a preinvasive stage with the premise that an important rate will be eligible for curative resection, improving overall survival. 6, 7 So, as previously stated in the literature, fitness for eventual surgery and/or Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com
Rodrigues RV, et al. Intensive follow-up after curative surgery for colorectal cancer, Acta Med Port 2017 Sep;30 (9) :633-641 systemic therapy is a necessary condition for a surveillance program. 8 Advantages of more intensive follow-up for patients treated for stage II and/or stage III disease have been demonstrated prospectively in several studies [9] [10] [11] [12] and in three meta-analyses of randomized controlled trials designed to compare low-intensity to high-intensity programs of surveillance. [13] [14] [15] Given the variation in surveillance regimens noted in the literature, it is not surprising that guidelines regarding CRC surveillance also vary considerably in their recommendations, although generically they all include periodic clinical evaluation, a carcinoembryonic antigen (CEA) assay and computed tomography. [16] [17] [18] [19] A prospective surveillance program with centralized nurse-led data collection was implemented at our institution in 2008; physically fit patients with surgically resected CRC, stages II and III were eligible. The aim of this study was to evaluate the rate of surgical treatment of recurrence with curative intent in our program; secondary outcomes were: colorectal cancer mortality, time to detection of recurrence, survival after treatment of recurrence with curative intent, evaluation of clinical characteristics associated with nonresectable recurrence and diagnostic accuracy of the surveillance model.
MATERIAL AND METHODS
In March 2008 we implemented a 5-year CRC surveillance program at Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE (IPOLFG) coordinated by registered nurses and Gastroenterologists. A minimum dataset was devised and maintained prospectively to evaluate the clinical effectiveness of the surveillance program. After curative-intent surgery and eventual adjuvant chemotherapy, patients are enrolled in their first post-treatment visit.
This was a cohort, single-center study. We included all patients in the intensive surveillance program between 03/2008 and 01/2015, with at least one determination of any of the surveillance methods and a monitoring visit. Our institutional review committee approved the protocol. Patients provided informed consent for participation in this surveillance program.
Surveillance protocol
The surveillance program consists of periodic clinical assessment, CEA and cancer antigen testing every three months for three years and then every six months for two more years, chest, abdominal and pelvic CTs once a year for the first three years and a follow-up colonoscopy within one year of surgery and then three years after (Table 1) . A clinic nurse reviews the test results, and abnormal results are forwarded to the patient's attending physician for further management. The patients attend the clinic in person at least once a year to review test results and have a physical examination.
Inclusion
Patients aged 18 years or older were eligible for inclusion if they had a confirmed diagnosis of colorectal adenocarcinoma stage II or III and had, at the IPOLFG multidisciplinary team, been allocated for treatment with curative intent. All patients on the intensive surveillance protocol between March 2008 and January 2015, with at least one determination of any of the methods and a monitoring visit, were included.
Exclusion
Patients were excluded if they were treated with palliative intent (R1 or R2 resection), if they were older than 80 years or if they had significant comorbidities that would prevent curative treatment of recurrence. Patients were also excluded if they did not accept participation in the surveillance program or have a colorectal adenocarcinoma stage I or IV because they have a different follow-up program (only colonoscopy for stage I and tighter imaging surveillance for stage IV, coordinated by oncologists).
Patient-related variables
Data were collected regarding: patient demographics, tumor characteristics, local and/or systemic treatment history, initial clinical staging, dates and results of surveillance investigations (CEA and CA 19-9 tests, CTs, and colonoscopies), recurrence demographics and management, and survival outcomes.
We considered rectal cancer all those that are located ≤ 15 cm from the anal verge; in case of disagreement between diagnostic tests, rigid proctoscopy was considered the gold standard.
Recurrences were classified as locoregional, including pelvic or perineal for rectal cancer, local lymph node or anastomotic or distant, including liver, lung, peritoneal and distant lymph node metastasis. If more than one site of distant metastasis was detected, the patient was classified as having disseminated disease. In case of a symptom-driven diagnosis of recurrence, patients were classified as symptomatic. The following signs or symptoms were appreciated: change in bowel habits, abdominal or perineal pain, hematochezia, abdominal mass, palpable hepatomegaly, jaundice, anorexia or weight loss. The result of the various examinations at the time of diagnosis or suspicion of recurrence was recorded and, thus, we were able to evaluate sensitivity and specificity.
Tumor markers were considered abnormal if increased above the superior reference value (CEA > 3 U/mL for non-smokers and > 5 U/mL for smokers and CA 19-9 > 37 U/mL). Liver and lung recurrences were diagnosed by imaging. In the case of anastomotic, perineal or pelvic recurrence, biopsy for histological confirmation was carried out. Regarding to colonoscopy findings: low-risk adenoma refers to patients with tubular adenomas, < 10 mm in diameter and low-grade dysplasia; high-risk adenoma refers to patients with tubular adenoma ≥ 10 mm, adenoma with villous histology, or high-grade dysplasia.
In patients undergoing surgery for relapse with a curative intent, the outcome was recorded, namely in the event of a second relapse and its treatment.
Statistical analysis
Descriptive statistical analysis was conducted to summarize baseline characteristics of the study population and separately for patients diagnosed with disease recurrence. Overall survival was measured from the date of diagnosis to the date of death due to any cause. Survival after recurrence was measured from the date of recurrence to the date of death due to any cause. Patients who were disease free or were alive at the last follow-up date were 
RESULTS

Baseline characteristics
In total, 404 patients met inclusion criteria, with a mean age at diagnosis of 64.56 years (25 -80) . The disease location was the rectum in 50.7% (n = 205) and the colon in 49.3% (n = 199). The clinical stage according to the 7 th AJCC classification was stage II in 43.8% (n = 177) and stage III in 56.3% (n = 227). Other important patient, treatment and disease baseline characteristics are shown in Table 2 .
Surveillance program
After an average time of follow-up of 37 months (3 -79) the recurrence rate was 12.9% (n = 52), mostly detected in the first three years (88.4%). Recurrence detection was due to elevation of tumor markers in 46.2% (n = 24), CT in 40.4% (n = 21), colonoscopy in 7.7% (n = 4) and symptoms in 5.8% (n = 3) of patients.
Among patients with recurrence, 18 had changes on surveillance CT alone, with the remaining relapse detection methods in the normal range; six showed only elevated CEA; and three had only elevated CA 19-9 -all these three patients showed disseminated disease when further studied. The accuracy of each tumor marker and CT in recurrence detection is described in Table 3 .
Surveillance colonoscopy detected three local recurrences of rectal tumors, three synchronous tumors and two metachronous tumors. Surveillance colonoscopy also detected low-risk adenomas in 76 patients (20.7% of those submitted to colonoscopy, n = 367) and high-risk adenomas in 22 patients (5.9% of those submitted to colonoscopy, n = 367).
Recurrence
Characteristics of the 52 patients with documented tumor recurrence are outlined in Table 4 . There were 11.5% locoregional recurrences (n = 6) and 88.5% metastatic recurrences (n = 46).
Among the 29 patients with rectal tumors with recurrence, we registered 14 lung, six locoregional (three of them anastomotic,) four liver, one distant lymph node and one peritoneal recurrence; there were three cases of disseminated disease. Among the 23 patients with colonic cancer with recurrence we reported eight liver, three peritoneal, one distant lymph node, one lung and three distant recurrences with involvement of other organs (brain, soft tissue/skin); there were seven disseminated disease cases. The pattern of recurrence was significantly associated with the location of the primary tumor (p < 0.001), with liver and disseminated disease recurrences being more frequent in colonic tumors while lung and locoregional recurrences were more common in rectal tumors.
Twenty-one patients underwent curative resection (R0 resection): lung (n = 8), liver (n = 7), colon or rectum (n = 2), liver and colorectal (n = 1), brain (n = 1) and soft tissue (n = 2) resections.
Patients in whom R0 resection was attempted but failed were considered palliative for further analysis.
Survival
A new relapse was detected in eight patients who underwent therapy with curative intent for their first recurrence (R0 resection); three of them were submitted to surgical treatment and only one is free of disease after the second relapse therapy with curative intent.
After recurrence the average time of follow-up was 15 months (1 -49). Two-year survival was 95.2% if curative surgery was performed (R0 resection) versus 59.9% for non-resectable recurrence (Kaplan-Meier log-rank, p = 0.016) (Fig. 1A) .
The average overall survival was 56 months in patients with relapse who underwent a curative lung surgery (n = 8) and 38 months in the group of patients submitted to a curative liver surgery after relapse (n = 8) (Wilcoxon rank sum test, p = 0.015) without significant difference in time of recurrence compared to initial surgery.
The global 5-year survival for the study population was 94.3% (Fig. 1B) . The overall rate of cancer-specific mortality was 2.2% (n = 9).
Factors associated with non-resectable recurrence
The univariate and multivariate analysis of potential factors associated with non-resectable recurrence are documented in Tables 5 and 6 , respectively. After multivariate analysis the only clinical factors associated with non-resectable recurrence were age ≥ 70 years (p = 0.022), and colonic location of the tumor (p = 0.033); CA 19-9 elevation was the only altered surveillance test associated with non-resectable disease (p = 0.024) ( Table 6 ). 
DISCUSSION
Disease recurrence occurred in less than a fifth of patients (n = 52, 12.9% of 404 patients), whereas previous studies report a recurrence rate of approximately 30% to 50%. 2, 3 Of note, the mean duration of surveillance was 37 months; therefore, it is possible that additional recurrences will be diagnosed with further follow-up.
The great majority of the patients had recurrence detected on the first three years after curative surgery (88.4%), which is in agreement with previous literature, where a more intensive surveillance during the first three years is advocated. [2] [3] [4] [5] Nonetheless it is also known that surveillance for multi-modal-treated rectal cancers should continue beyond five years, as perioperative treatment might delay recurrence beyond this time point. 20 Our study demonstrated that most recurrences were diagnosed by surveillance investigations (n = 49, 94.2% of 52 patients). The initial abnormal surveillance test leading to the diagnosis of recurrence was an alteration of tumor markers (CEA or CA 19-9) in 24 patients, of CT imaging Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com in 21 patients, and of colonoscopy in four patients. The high negative predictive value of aggregate surveillance test reflects both the low prevalence of recurrence and the high aggregate sensitivity in recurrence diagnosis. CEA had a low positive predictive value, and there was a high false positive rate for a single isolated CEA level elevation, reinforcing the need for subsequent confirmation of further abnormal measurements before initiating imaging studies, as previously reported. 21 Despite not being part of surveillance programs adopted by several international societies [15] [16] [17] [18] [19] we decided to include the determination of CA 19-9 on our surveillance program based on a previous study carried out at our institution that showed an incremental benefit of the inclusion of this tumor marker on the diagnosis of recurrence. 22 However, in our study, the patients whose recurrence was detected by an isolated elevation of CA 19-9 had advanced disseminated disease without the possibility of curative therapy, so we consider that there was no benefit from the inclusion of this tumor marker in the follow-up program.
Colonoscopy is an important component of surveillance and allows the detection of relapses with endoluminal expression, having a crucial role mainly in rectal tumors. However, it's major interest lies in the detection of metachronous adenomas and carcinomas during follow--up. 11, [15] [16] [17] This is highlighted in our study by the observation that new adenomas were diagnosed in more than onequarter of patients who underwent surveillance colonoscopy (n = 98, 26.7% of 367 patients). Malignancy was diagnosed in 8 (2.2% of 367 patients) with anastomotic recurrence in three of these patients (1.5% of 205 patients with rectal cancer). Our data is in line with previous studies that found metachronous lesions in 1.5 to 3% of patients in the first three to five years postoperatively and local recurrence occurs in less than 5% of patients with rectal cancer. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Early detection of recurrence in the asymptomatic phase in most patients allowed curative intent treatment strategies for more than one third of patients (n = 21, 40.3%). The pattern of recurrence was associated with the site of the primary tumor (p < 0.001). In rectal tumors we highlight pulmonary metastasis (n = 14) and locoregional relapse (n = 6), including anastomotic. In colonic tumors the recurrence pattern favored liver metastasis (n = 8) and disseminated disease (n = 7). The higher rate of disseminated disease in colon cancer patients likely explains the association between colon cancer and non-resectable recurrence. These findings, like previous studies, suggest that developing approaches for adjusting the intensity of CRC surveillance tests based on primary tumor location may improve our ability to detect CRC recurrences at a more treatable stage. 35 Probably personalized, risk stratified surveillance programs should be designed, like liver oriented surveillance for colonic cancer and lung oriented surveillance as well local oriented surveillance for rectal cancer. We have shown that anatomical location of the primary CRC tumor and age ≥ 70 years were independent predictors of non-resectable recurrence -the validation of these variables in prospective studies involving a large number of patients may assist in building models to target which patients should enter intensive follow-up strategies.
The limitations of the current study were the single center design and the lack of comparator arms, but otherwise it describes the results of a real-world surveillance program.
CONCLUSION
In conclusion, since the goal of this study was to demonstrate a clinical benefit (number of successful R0 resections) of intensive CRC surveillance, we assume that the objective was achieved as is demonstrated by the number of patients undergoing curative surgery for recurrence (40.3%). Nevertheless, given the low rate of recurrences, the overall benefit applies to only 5% of the patients included in the surveillance program. 
